Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celestial-2: FE 999302 in women undergoing controlled ovarian stimulation
NCT06511791Phase 1Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of choriogonadotropin beta in infertility (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Number of good-quality blastocysts at Day 5. Started Jul 2024; status: terminated.
02
Drugs
choriogonadotropin beta
03
Conditions
infertility
Beyond the preview
Go deeper on NCT06511791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511791.